HPA045910

antibody from Atlas Antibodies

Targeting: CRBN MRT2, MRT2A

Provider product page for HPA045910

Western blot

Immunocytochemistry

Antibody data

Antibody Data
Antigen structure
References [28]
Comments [0]
Validations
Western blot [1]
Immunocytochemistry [1]

Submit

Product number: HPA045910 - Provider product page
Provider: Atlas Antibodies
Proper citation: Atlas Antibodies Cat#HPA045910, RRID:AB_10960409
Product name: Anti-CRBN
Antibody type: Polyclonal
Description: Polyclonal Antibody against Human CRBN, Gene description: cereblon, Alternative Gene Names: MRT2, MRT2A, Validated applications: ICC, WB, Uniprot ID: Q96SW2, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Reactivity: Human, Mouse, Rat
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 100 µl
Concentration: 0.2 mg/ml
Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Handling: The antibody solution should be gently mixed before use.

CRBN protein structure - HPA045910 shown in red.

Submitted references A Tandem-Affinity Purification Method for Identification of Primary Intracellular Drug-Binding Proteins

Islam S, Gour J, Beer T, Tang H, Cassel J, Salvino J, Busino L
ACS Chemical Biology 2024;19(2):233-242

Maddineni A, Liang Z, Jambardi S, Roy S, Tycko J, Patil A, Manzano M, Gottwein E
2024

Activity-based profiling of cullin–RING E3 networks by conformation-specific probes

Henneberg L, Singh J, Duda D, Baek K, Yanishevski D, Murray P, Mann M, Sidhu S, Schulman B
Nature Chemical Biology 2023;19(12):1513-1523

Direct-to-biology, automated, nano-scale synthesis, and phenotypic screening-enabled E3 ligase modulator discovery

Wang Z, Shaabani S, Gao X, Ng Y, Sapozhnikova V, Mertins P, Krönke J, Dömling A
Nature Communications 2023;14(1)

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma

Domenger A, Ricci D, Mayau V, Majlessi L, Marcireau C, Dadaglio G, Demangel C
Frontiers in Oncology 2023;13

A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells

Zhang K, Gao L, Wang J, Chu X, Zhang Z, Zhang Y, Fang F, Tao Y, Li X, Tian Y, Li Z, Sang X, Ma L, Lu L, Chen Y, Yu J, Zhuo R, Wu S, Pan J, Hu S
Pathology and Oncology Research 2022;28

Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases

Luo X, Archibeque I, Dellamaggiore K, Smither K, Homann O, Lipford J, Mohl D
iScience 2022;25(3):103985

The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma

Jia S, Zhuo R, Zhang Z, Yang Y, Tao Y, Wang J, Li X, Xie Y, Li G, Wu D, Chen Y, Yu J, Feng C, Li Z, Zhou R, Yang R, Yang P, Zhou B, Wan X, Wu Y, Jiao W, Zhou N, Fang F, Pan J, Zhong J
Journal of Immunology Research 2022;2022

Long-term depletion of cereblon induces mitochondrial dysfunction in cancer cells

Park S, Kim K, Haam K, Ban H, Kim J, Park B, Park S, Kim S, Kim J
BMB Reports 2021;54(6):305-310

Cereblon Regulates the Proteotoxicity of Tau by Tuning the Chaperone Activity of DNAJA1

Akber U, Jo H, Jeon S, Yang S, Bong S, Lim S, Kim Y, Park Z, Park C
The Journal of Neuroscience 2021;41(24):5138-5156

BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes

Wu S, Jiang Y, Hong Y, Chu X, Zhang Z, Tao Y, Fan Z, Bai Z, Li X, Chen Y, Li Z, Ding X, Lv H, Du X, Lim S, Zhang Y, Huang S, Lu J, Pan J, Hu S
Cancer Cell International 2021;21(1)

Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2

Lieberman P, Shrestha P, Davis D, Jaeger H, Stream A, Aisabor A, Yarchoan R
PLOS Pathogens 2021;17(1):e1009091

Regulation of AMPK Activity by CRBN Is Independent of the Thalidomide-CRL4CRBN Protein Degradation Axis

Yang S, Jeon S, Baek J, Lee K, Park C
Pharmaceuticals 2021;14(6):512

Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition

Petillo S, Capuano C, Molfetta R, Fionda C, Mekhloufi A, Pighi C, Antonangeli F, Zingoni A, Soriani A, Petrucci M, Galandrini R, Paolini R, Santoni A, Cippitelli M
Cell Death & Disease 2021;12(9)

ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways

Liao X, Qian X, Zhang Z, Tao Y, Li Z, Zhang Q, Liang H, Li X, Xie Y, Zhuo R, Chen Y, Jiang Y, Cao H, Niu J, Xue C, Ni J, Pan J, Cui D
Frontiers in Oncology 2021;11

The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K

Słabicki M, Kozicka Z, Petzold G, Li Y, Manojkumar M, Bunker R, Donovan K, Sievers Q, Koeppel J, Suchyta D, Sperling A, Fink E, Gasser J, Wang L, Corsello S, Sellar R, Jan M, Gillingham D, Scholl C, Fröhling S, Golub T, Fischer E, Thomä N, Ebert B
Nature 2020;585(7824):293-297

Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs

Beedie S, Huang P, Harris E, Strope J, Mahony C, Chau C, Vargesson N, Figg W
The FASEB Journal 2020;34(9):11395-11404

Crbn modulates calcium influx by regulating Orai1 during efferocytosis

Moon H, Min C, Kim G, Kim D, Kim K, Lee S, Moon B, Yang S, Lee J, Yang S, Cho S, Lee G, Lee C, Park C, Park D
Nature Communications 2020;11(1)

PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc

Li Z, Lim S, Tao Y, Li X, Xie Y, Yang C, Zhang Z, Jiang Y, Zhang X, Cao X, Wang H, Qian G, Wu Y, Li M, Fang F, Liu Y, Fu M, Ding X, Zhu Z, Lv H, Lu J, Xiao S, Hu S, Pan J
Frontiers in Oncology 2020;10

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

Zhu Y, Shi C, Bruins L, Wang X, Riggs D, Porter B, Ahmann J, de Campos C, Braggio E, Bergsagel P, Stewart A
Blood Cancer Journal 2019;9(2)

Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera

Kim K, Lee D, Park S, Jo S, Ku B, Park S, Park B, Jeon Y, Ahn S, Kang C, Hwang D, Chae S, Ha J, Kim S, Hwang J, Kim J
Scientific Reports 2019;9(1)

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation

Zhou N, Gutierrez-Uzquiza A, Zheng X, Chang R, Vogl D, Garfall A, Bernabei L, Saraf A, Florens L, Washburn M, Illendula A, Bushweller J, Busino L
Leukemia 2019;33(8):2006-2021

The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors

Abruzzese M, Bilotta M, Fionda C, Zingoni A, Soriani A, Petrucci M, Ricciardi M, Molfetta R, Paolini R, Santoni A, Cippitelli M
Cell Death & Disease 2019;10(4)

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner

Dimopoulos K, Søgaard Helbo A, Fibiger Munch‐Petersen H, Sjö L, Christensen J, Sommer Kristensen L, Asmar F, Hermansen N, O'Connel C, Gimsing P, Liang G, Grønbæk K
Molecular Oncology 2017;12(2):180-195

p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates

Nguyen T, Li J, Lu C, Mamrosh J, Lu G, Cathers B, Deshaies R
Proceedings of the National Academy of Sciences 2017;114(14):3565-3571

Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration

Del Prete D, Rice R, Rajadhyaksha A, D'Adamio L
Journal of Biological Chemistry 2016;291(33):17209-17227

Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN production

Millrine D, Tei M, Gemechu Y, Kishimoto T
Proceedings of the National Academy of Sciences 2016;113(38):10625-10630

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

Gandhi A, Mendy D, Waldman M, Chen G, Rychak E, Miller K, Gaidarova S, Ren Y, Wang M, Breider M, Carmel G, Mahmoudi A, Jackson P, Abbasian M, Cathers B, Schafer P, Daniel T, Lopez‐Girona A, Thakurta A, Chopra R
British Journal of Haematology 2013;164(2):233-244

No comments: Submit comment

Enhanced validation

Submitted by: Atlas Antibodies (provider)
Enhanced method: Genetic validation
Main image
Experimental details: Western blot analysis in HEK293 cells transfected with control siRNA, target specific siRNA probe #1, using Anti-CRBN antibody. Remaining relative intensity is presented. Loading control: Anti-GAPDH.
Sample type: Human
Protocol: Protocol

Supportive validation

Submitted by: Atlas Antibodies (provider)
Main image
Experimental details: Immunofluorescent staining of human cell line U-251 MG shows localization to nucleoli.
Sample type: Human